 |
|
Funding round for OGeS
Ambitious drug developer Oxford Genome Sciences (OGeS) has secured private equity funding of an undisclosed sum from a syndicate of investors. The funding round was led by Catapult Growth Fund and included South East Growth Fund and Oxford Capital Partners.
With the funding, OeGS aims to develop personalised drug therapies for cancer and Alzheimer’s disease. The deal is the first investment for Catapult, a newly-launched £30 million fund. The other two funders have backed OeGS before.
Chief executive Christian Rohlff says that the 'additional funds provide us with financing visibility for the next three years'.
Oxford-based OGeS was founded in 2004. During the past year, the company has entered into partnerships with businesses in the therapeutic and diagnostic industries, such as US company Bayer HealthCare Diagnostics.
Related Articles |
Interesting links
Other Sector Watch
- Investment veteran airs fears over UK biotech Oct 21 2008
- Talking rubbish Jul 28 2008
- Crisis?– what crisis? Jul 01 2008
- Let the
drilling begin
May 13 2008 - Bargains on the high street
Mar 13 2008
M&A News
- Hertford cashes in on Cheque Exchange Nov 20 2008
- Talbot Hughes McKillop’s Kroll MBO Nov 20 2008
- Cabinet member calls for more VC Nov 19 2008
- United Drug takes The Specials Lab medicine Nov 19 2008
- Public-to-private deals on the up Nov 18 2008
Special Offers
- 2008 AIM Guide: Jul 17 2007
- Growth Company Investor Magazine: Jul 17 2007
- Cash Shells 2007 - Research report Jul 17 2007
- Venture Capital Trusts Jul 04 2007
M&A Deals
- Amino Technologies to acquire Tilgin division Nov 20 2008
- Wincanton and Culina make chilled deal Nov 20 2008
- Devilfish makes Paramin Poker deal Nov 19 2008
- Arriva closes LNWR train maintenance deal Nov 19 2008
- UBM buys Xinhua PR Newswire Nov 18 2008
Business Diary
- M&A Expanding internationally 27th November
- Rosenblatt New Energy Awards 2009 25th February